Goldman Sachs Group Inc. Acquires 6,549 Shares of Enanta Pharmaceuticals, Inc. $ENTA

Goldman Sachs Group Inc. lifted its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 5.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,410 shares of the biotechnology company’s stock after buying an additional 6,549 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Enanta Pharmaceuticals were worth $720,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ENTA. Millennium Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 50.2% in the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after buying an additional 449,945 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 674.7% in the first quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after buying an additional 311,010 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 78.0% in the first quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company’s stock valued at $3,261,000 after buying an additional 258,842 shares during the last quarter. Trexquant Investment LP raised its holdings in shares of Enanta Pharmaceuticals by 113.4% in the first quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 154,105 shares during the last quarter. Finally, PDT Partners LLC raised its holdings in shares of Enanta Pharmaceuticals by 217.5% in the first quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company’s stock valued at $586,000 after buying an additional 72,751 shares during the last quarter. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Down 6.9%

NASDAQ:ENTA opened at $7.17 on Wednesday. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.09 and a twelve month high of $13.37. The business has a 50 day moving average price of $7.92 and a two-hundred day moving average price of $6.80. The company has a market cap of $153.29 million, a P/E ratio of -1.66 and a beta of 0.84.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. As a group, analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ENTA shares. JMP Securities boosted their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Evercore ISI dropped their price objective on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a report on Monday, September 15th. HC Wainwright started coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Finally, Westpark Capital started coverage on Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They set a “buy” rating and a $24.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Enanta Pharmaceuticals has a consensus rating of “Buy” and an average price target of $20.20.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.